Levodopa Induced Dyskinesia in Patients With Parkinson's Disease Clinical Trial
The proposed study is to evaluate the safety and initial effectiveness of the ExAblate
Transcranial MRI-guided focused ultrasound (MRgFUS) treatment of patients with dyskinesia of
Parkinson's Disease (PD)
- Safety: To evaluate the incidence and severity of adverse events (AE/AEs) associated
with ExAblate Transcranial MRgFUS treatment of dyskinesia of PD
- Effectiveness: To determine the level of effectiveness of the ExAblate Transcranial
MRgFUS treatment of dyskinesia of PD.Efficacy will be determined utilizing the UPDRS-IV
for dyskinesia in PD from examinations at baseline and every 3-Months post-ExAblate
treatment.
This study is designed as a prospective, single-site, single arm, nonrandomized study.
Assessments will be made before and three months after MRgFUS for clinical symptom relief,
quality of life (QoL) improvements, and safety of MRgFUS in the treatment of LID. Relative
Safety will be evaluated using a common description of Significant Clinical Complications for
patients treated in this study. This study will be performed on the 3T MR scanners.
n/a